GABriella, a Phase 2a study investigating the gamma‐secretase modulator RG6289 in individuals at risk for and at the prodromal stage of Alzheimer’s disease: baseline characteristics of the recruited participants

GABriella is the first clinical trial assessing the effects of a brain-penetrant, potent, and selective GSM in amyloid-positive individuals, who are either CU or have MCI due to AD. This study will provide critical insights into the safety, tolerability, and pharmacodynamic effects of RG6289 on key AD-related biomarkers. The results will contribute to understanding the potential of GSM therapy in the early stages of AD.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70861_108331
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

GABriella, a Phase 2a study investigating the gamma‐secretase modulator RG6289 in individuals at risk for and at the prodromal stage of Alzheimer’s disease: baseline characteristics of the recruited participants

Christoph Wandel, Lisa Squassante, Geoffrey A. Kerchner, Thomas Mueggler et al.
Alzheimer s & Dementia
Alzheimer's disease research and treatments
article

GABriella, a Phase 2a study investigating the gamma‐secretase modulator RG6289 in individuals at risk for and at the prodromal stage of Alzheimer’s disease: baseline characteristics of the recruited participants

Christoph Wandel, Lisa Squassante, Geoffrey A. Kerchner, Thomas Mueggler, Luka Kulic, Julie Cook, Irene Gerlach, Irma T. Kurniawan, Anand Nair, Stefan Buck, Natasha O'Sullivan, Petr Novak, Enrique Gaspar, Ana Maria Buehlmann, Rosanna Tortelli, Tianxu Yang, Tayo Bodede
article en

Abstract

GABriella is the first clinical trial assessing the effects of a brain-penetrant, potent, and selective GSM in amyloid-positive individuals, who are either CU or have MCI due to AD. This study will provide critical insights into the safety, tolerability, and pharmacodynamic effects of RG6289 on key AD-related biomarkers. The results will contribute to understanding the potential of GSM therapy in the early stages of AD.

Alzheimer s & DementiaVol. 21(S7)
Roche (Switzerland) (CH), Roche (United Kingdom) (GB), Roche (China) (CN)
Good health and well-being
Openalex Percentile: Top 34%
Alzheimer's disease research and treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

GABriella, a Phase 2a study investigating the gamma‐secretase modulator RG6289 in individuals at risk for and at the prodromal stage of Alzheimer’s disease: baseline characteristics of the recruited participants — Christoph Wandel, Lisa Squassante, et al. · Alzheimer s & Dementia (2025) | TGRS Research Map | TGRS